Skip to main content
RecallsAboutBlog

Cipla USA, Inc.

Cipla USA, Inc.: 7 recalls listed since January 2026 across FDA.

By year

  • 20267

By agency

  • FDA7

By category

  • Drug7

All recalls (7)

Cipla USA Fosfomycin Tromethamine Granules for Oral Solution

Fosfomycin Tromethamine Granules for Oral Solution failed impurities and degradation specifications.

Moderate risk, FDA, , Drug impurity

Cipla Cinacalcet Hydrochloride Tablets

CGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).

Moderate risk, FDA, , Drug impurity

Cipla Cinacalcet Hydrochloride Tablets

Cipla is recalling its Cipla Cinacalcet Hydrochloride Tablets because of CGMP deviations and presence N-Nitroso Cinacalcet above the acceptable daily intake limit.

Moderate risk, FDA, , Drug impurity

Cipla Lanreotide Injection

Lanreotide Injection lacks assurance of sterility due to deficiencies in visual inspection.

Moderate risk, FDA, , Sterility problem

Cipla Nilotinib Capsules

Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection test.

Low risk, FDA, , Quality testing problem

Cipla Diclofenac Sodium Topical Gel 1%

Diclofenac Sodium Topical Gel, 1% failed pH specifications.

Low risk, FDA, , Quality testing problem

Cipla USA Lanreotide Injection

Lanreotide Injection contains particulate matter.

Moderate risk, FDA, , Foreign object
Embed this list